Program
Atorvastatin
Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.
Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.
Drug pageAtorvastatin: every studyMany companies study it; this page follows only the 105 they lead. All 640 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 290 open or running | phase 4since Aug 30, 2005 | Aug 25, 2005 | none ahead |
| Organonits history only | 200 open or running | phase 4since Apr 1, 2008 | Sep 23, 2004 | none ahead |
| Pfizerits history only | 160 open or running | phase 4since Sep 6, 2005 | Aug 22, 2005 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 60 open or running | phase 4since Nov 16, 2009 | Nov 16, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 60 open or running | phase 1since Jul 18, 2012 | Jul 18, 2012 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Dec 15, 2011 | Dec 11, 2006 | none ahead |
| Astellas Pharmaits history only | 30 open or running | phase 4since Dec 5, 2006 | Dec 5, 2006 | none ahead |
| Daiichi Sankyoits history only | 30 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| midas-pharma-gmbhits history only | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Dec 20, 2011 | Dec 20, 2011 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Sep 21, 2012 | Sep 21, 2012 | none ahead |
| clinical-research-management-incits history only | 10 open or running | phase 2since Mar 1, 2015 | Mar 1, 2015 | none ahead |
| Cumberland Pharmaceuticalsits history only | 10 open or running | phase 2since Jul 19, 2018 | Jul 19, 2018 | none ahead |
| Daewon Pharmaceuticalits history only | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| dr-md-alimur-rezaits history only | 10 open or running | phase 4since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Huons Globalits history only | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Jeil Pharmaceuticalits history only | 10 open or running | phase 1since Mar 5, 2018 | Mar 5, 2018 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 10 open or running | phase 3since Apr 29, 2021 | Apr 29, 2021 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 9, 2009 | Sep 9, 2009 | none ahead |
| samil-pharmaceutical-co-ltdits history only | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: Parexel, Pharma Medica Research, Merck, Regeneron Pharmaceuticals, MDS Pharma Services, Celerion, Sanofi and Basilea Pharmaceutica International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Mar 26, 2008.
- Oct 26, 2016Daewoong Pharmaceutical’s first study: phase 3 study in Diabetes Mellitus, Type 2New to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT02947620 · 185 enrolled · Korea, Republic of
- Nov 27, 2016Phase 2 study in DyslipidemiasChong Kun Dang Pharmaceutical · NCT02977065 · 62 enrolled · Australia
- Jan 23, 2017Phase 1 study in Non-alcoholic Fatty Liver DiseasePfizer · NCT03031119 · 62 enrolled · Belgium
- Mar 5, 2018Jeil Pharmaceutical’s first study: phase 1 study in Hypertension With HyperlipidemiaNew to Jeil PharmaceuticalJeil Pharmaceutical · NCT03461081 · 32 enrolled · Korea, Republic of
- Jul 19, 2018Cumberland Pharmaceuticals’ first study: phase 2 study in HypercholesterolemiaNew to Cumberland PharmaceuticalsCumberland Pharmaceuticals · NCT03611010 · 40 enrolled · United States
- Mar 6, 20193 phase 3 studiesOrganon · NCT03884452, NCT03867318, NCT03867110
- Jan 23, 2020midas-pharma-gmbh’s first study: phase 1 study in Healthy VolunteersNew to midas-pharma-gmbhmidas-pharma-gmbh · NCT04245046 · 18 enrolled · Jordan
- Feb 7, 2020Phase 1 study in Healthy Volunteersmidas-pharma-gmbh · NCT04262765 · 18 enrolled · Jordan
- Apr 29, 2021Laboratorios Silanes S.A. de C.V.’s first study: phase 3 study in DyslipidemiasNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT04882293 · 78 enrolled · Mexico
- Oct 13, 2021Phase 1 study in Healthy AdultsPfizer · NCT05093205 · 35 enrolled · United States
- Jul 24, 2023Daewon Pharmaceutical’s first study: phase 3 study in HypercholesterolemiaNew to Daewon PharmaceuticalDaewon Pharmaceutical · NCT05970679 · 252 enrolled · Korea, Republic of
- Jan 17, 2025dr-md-alimur-reza’s first study: phase 4 study in HyperlipidemiasNew to dr-md-alimur-rezadr-md-alimur-reza · NCT06789432 · Bangladesh
- Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
- Aug 5, 2026Huons Global’s first study: phase 1 study in Drug-drug InteractionsNew to Huons GlobalHuons Global · NCT07784608 · 28 planned · South Korea
Ahead
- Apr 2027Primary completion: phase 1 study in Drug-drug InteractionsHuons Global · NCT07784608
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The newest 60 of 105 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07784608Drug-drug Interactions · South Korea | 1 | Not yet recruiting | Huons Global | Apr 2027 | 28 |
| NCT07268625Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Feb 24, 2026 | 58 |
| NCT07235189Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Jan 28, 2026 | 58 |
| NCT06789432Hyperlipidemias · Bangladesh | 4 | Withdrawn | dr-md-alimur-reza | Oct 2025 | 0 |
| NCT05970679Hypercholesterolemia · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Apr 13, 2023 | 252 |
| NCT05093205Healthy Adults · United States | 1 | Completed | Pfizer | Jul 6, 2022 | 35 |
| NCT04882293Dyslipidemias · Mexico | 3 | UNKNOWN | Laboratorios Silanes S.A. de C.V. | May 2022 | 78 |
| NCT04262765Healthy Volunteers · Jordan | 1 | Completed | midas-pharma-gmbh | Mar 26, 2019 | 18 |
| NCT04245046Healthy Volunteers · Jordan | 1 | Completed | midas-pharma-gmbh | Feb 18, 2019 | 18 |
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | Organon | May 24, 2001 | 50 |
| NCT03867318Hypercholesterolemia | 3 | Completed | Organon | Nov 16, 2001 | 621 |
| NCT03867110Hypercholesterolemia | 3 | Completed | Organon | Jul 27, 2001 | 628 |
| NCT03611010Hypercholesterolemia · United States | 2 | Completed | Cumberland Pharmaceuticals | Feb 17, 2020 | 40 |
| NCT03461081Hypertension With Hyperlipidemia · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Jul 12, 2017 | 32 |
| NCT03031119Non-alcoholic Fatty Liver Disease · Belgium | 1 | Completed | Pfizer | Jul 2017 | 62 |
| NCT02977065Dyslipidemias · Australia | 2 | Completed | Chong Kun Dang Pharmaceutical | Dec 30, 2017 | 62 |
| NCT02947620Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Feb 27, 2017 | 185 |
| NCT02641899Healthy · United States | 1 | Completed | Intarcia Therapeutics | Mar 2016 | 33 |
| NCT02579356Essential Hypertension · Korea, Republic of | 1 | Completed | samil-pharmaceutical-co-ltd | Aug 2014 | 48 |
| NCT02550288Hypercholesterolemia | 3 | Completed | Organon | May 30, 2016 | 309 |
| NCT02460159Hypercholesterolemia | 3 | Completed | Organon | Dec 22, 2016 | 135 |
| NCT02422030Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Mar 22, 2015 | 30 |
| NCT02380625Hemorrhagic Fever, Ebola | 2 | UNKNOWN | clinical-research-management-inc | Jan 2016 | 150 |
| NCT02295046Healthy · Germany | 1 | Completed | Dr. Reddy's Laboratories | Oct 2011 | 80 |
| NCT02292069Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2011 | 90 |
| NCT02288338Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Feb 2015 | 36 |
| NCT02066207Dyslipidemias · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 7, 2014 | 30 |
| NCT01964326Hypercholesterolemia · United States | 3 | Completed | Viatris | Dec 2014 | 1,311 |
| NCT01842256Essential Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 2013 | 24 |
| NCT01692717Healthy Subjects · Brazil | 1 | Completed | Azidus Brasil | May 31, 2013 | 90 |
| NCT01645449Healthy · Germany | 1 | Completed | Dr. Reddy's Laboratories | Aug 2010 | 77 |
| NCT01645423Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2009 | 77 |
| NCT01645410Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2009 | 71 |
| NCT01645384Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jun 2009 | 69 |
| NCT01635946Pharmacokinetics of Isavuconazole · United States | 1 | Completed | Astellas Pharma | Aug 2012 | 24 |
| NCT01499771Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Oct 2009 | 80 |
| NCT01499758Healthy · United States | 1 | Completed | Sun Pharmaceutical Industries | Oct 2009 | 80 |
| NCT01495013Diabetes Mellitus, Type 2 · Korea, Republic of, Malaysia, Mexico and more | 3 | Completed | GlaxoSmithKline | Apr 2013 | 427 |
| NCT01370603Hypercholesterolemia | 3 | Completed | Organon | May 2012 | 328 |
| NCT01370590Hypercholesterolemia | 3 | Completed | Organon | Apr 2012 | 406 |
| NCT01218204Dyslipidemias · United States | 2 | Completed | GlaxoSmithKline | Jun 29, 2011 | 287 |
| NCT01299597Sleep Wake Disorders · Germany | 1 | Completed | GlaxoSmithKline | Feb 26, 2010 | 30 |
| NCT01154036Hypercholesterolemia | 3 | Completed | Organon | Sep 2012 | 1,547 |
| NCT01138072Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2010 | 14 |
| NCT01115985Healthy · Japan | 1 | Completed | Astellas Pharma | Apr 2010 | 24 |
| NCT01029522Dyslipidemias | 4 | Completed | Chong Kun Dang Pharmaceutical | Oct 2008 | 244 |
| NCT00974740Diabetes Mellitus, Type 1 · Germany | 1 | Terminated | Profil Institut für Stoffwechselforschung | Jan 2008 | 63 |
| NCT00917579Hypercholesterolemia · United States | 4 | Completed | Viatris | Sep 2008 | 76 |
| NCT00871351Primary Hypercholesterolemia | 4 | Completed | Organon | May 1, 2010 | 125 |
| NCT00844376Hypercholesterolemia · United States | 4 | Completed | Viatris | Mar 2008 | 12 |
| NCT00827606Hyperlipoproteinemia Type II · United States, Belgium, Canada and more | 3 | Completed | Viatris | Oct 2013 | 272 |
| NCT00782184Hypercholesterolemia | 3 | Completed | Organon | Sep 2010 | 250 |
| NCT00758004Hypercholesterolemia · United States | 1 | Completed | Viatris | Mar 2009 | 76 |
| NCT00754507Hypercholesterolemia · United States | 4 | Completed | Daiichi Sankyo | Jun 2003 | 65 |
| NCT00739999Pediatric Heterozygous Hypercholesterolemia · Canada, Greece, Norway | 1 | Completed | Viatris | May 2009 | 39 |
| NCT00728988Acute Coronary Syndrome · China, Korea, Republic of | 4 | Completed | Viatris | Apr 2010 | 499 |
| NCT00654095Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 146 |
| NCT00653796Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 148 |
| NCT00650689Hypercholesterolemia | 3 | Completed | Organon | Dec 2004 | 122 |
| NCT00647543Dyslipidemias · Thailand | 4 | Completed | Viatris | 242 |
How it is read
Names in the registry
- “Atorvastatin”, 95 entries
- “atorvastatin”, 36 entries
- “Atorvastatin 20 mg”, 3 entries
- “Comparator: atorvastatin”, 3 entries
- “Atorvastatin 10 mg”, 3 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 48 studies
- Dyslipidemias, 15 studies
- Hyperlipidemias, 11 studies
- Diabetes Mellitus, Type 2, 9 studies
- Cardiovascular Diseases, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.